New drug trial targets debilitating endometriosis pain
NCT ID NCT07318688
Summary
This study aims to see if an investigational drug called HMI-115 can safely reduce moderate to severe pain caused by endometriosis. It will involve about 540 women who will receive either the drug or a placebo for 24 weeks, with an option to continue for another 28 weeks. The main goal is to measure changes in menstrual and non-menstrual pelvic pain.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ENDOMETRIOSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Nanjing Women and children's healthcare hospital
Nanning, Jiangsu, China
Contact
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100703, China
Contact
-
Second Affiliated Hospital of Soochow University
Suzhu, Jiangsu, China
-
The International Peace Maternity and Child Health Hospital of the China Welfare Institute
Shanghai, Shanghai Municipality, China
Contact
-
Tianjin Medical University General Hospital
Tianjin, Tianjin Municipality, China
Contact
Conditions
Explore the condition pages connected to this study.